Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Two JNJ-64304500 Formulations in Healthy Participants
NCT04667052Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2021
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of NNC0142-0002 in Crohn's disease (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Serum Concentration and Area Under the Serum Concentration-Time Curve From Time Zero to Time Infinity. Started Jan 2021; status: completed.
02
Drugs
NNC0142-0002
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04667052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04667052.